Hospital
Huntsville Community Hospital, INC.
Huntsville Community Hospital, INC. was paid $3.29M by Medicaid between Mar 2020 and Nov 2024, across 73 billing codes. Its largest line is 99284, emergency room visit (serious) — 53% of everything it billed.
33Billing provider infoHUNTSVILLE COMMUNITY HOSPITAL, INC.
HUNTSVILLE, TX 77340
HUNTSVILLE, TX 77340
33aNPI1245878990assigned 12/12/2019
33bProvider typeGeneral Acute Care Hospital
28Total paid$3.29M
24GClaims46,630
24DCodes billed73
24AFirst – last monthMar 2020 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Texas
Rank by total paid#43 of 109
Median peer was paid$1.15M
This provider vs. median2.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 2,017 | $140K | |
| 2021 | 9,767 | $525K | |
| 2022 | 13,593 | $962K | |
| 2023 | 16,266 | $1.35M | |
| 2024incomplete | 4,987 | $316K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 53% | 4,319 | 4,034 | $1.74M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 20% | 1,481 | 1,366 | $657K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 4,296 | 4,029 | $358K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.5% | 2,070 | 1,956 | $116K |
| 80053 | Comprehensive metabolic panel | 1.5% | 4,829 | 4,321 | $50K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 6,119 | 5,470 | $43K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 1.1% | 761 | 742 | $35K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.0% | 863 | 815 | $34K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 773 | 730 | $33K |
| 87400 | <1% | 998 | 942 | $33K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 379 | 341 | $28K |
| 87806 | <1% | 516 | 491 | $20K |
61 more codes
| 87430 | <1% | 780 | $16K | |
| 81514 | <1% | 41 | $15K | |
| 71045 | Radiologic examination, chest; single view | <1% | 624 | $14K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 606 | $12K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 679 | $9K |
| 81001 | <1% | 3,072 | $9K | |
| 87070 | <1% | 701 | $7K | |
| 87088 | <1% | 911 | $6K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 889 | $6K |
| 80061 | Lipid panel | <1% | 650 | $6K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 134 | $4K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 210 | $4K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 13 | $3K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 67 | $3K |
| 87420 | <1% | 169 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 412 | $3K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 26 | $2K |
| 86592 | <1% | 414 | $2K | |
| CP007 | <1% | 49 | $2K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 14 | $2K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 44 | $2K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 35 | $2K |
| 86803 | <1% | 107 | $2K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 44 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 39 | $1K |
| 85004 | <1% | 229 | $1K | |
| 83498 | <1% | 29 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 87 | $811.38 |
| 84439 | <1% | 77 | $770.55 | |
| 84484 | <1% | 263 | $693.01 | |
| 83690 | <1% | 95 | $630.27 | |
| 86780 | <1% | 30 | $576.01 | |
| 83874 | <1% | 184 | $572.61 | |
| 86850 | <1% | 26 | $554.59 | |
| 86787 | <1% | 29 | $523.48 | |
| 82553 | <1% | 182 | $521.64 | |
| 81025 | <1% | 67 | $501.58 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 215 | $486.56 |
| 82947 | <1% | 93 | $457.81 | |
| 82550 | <1% | 270 | $451.12 | |
| 85610 | <1% | 179 | $427.94 | |
| 85730 | <1% | 87 | $340.83 | |
| 87340 | <1% | 25 | $327.14 | |
| 84702 | <1% | 16 | $324.20 | |
| 36000 | <1% | 28 | $243.84 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 27 | $181.14 |
| 83735 | <1% | 95 | $159.24 | |
| 84703 | <1% | 13 | $141.88 | |
| 82150 | <1% | 13 | $120.12 | |
| 86900 | <1% | 26 | $109.23 | |
| 86901 | <1% | 26 | $109.23 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,765 | $99.39 |
| 83880 | <1% | 29 | $98.94 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 12 | $69.08 |
| 87186 | <1% | 30 | $42.90 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 83 | $26.05 |
| 0353U | <1% | 26 | $7.74 | |
| J3490 | Unclassified drugs | <1% | 20 | $0.71 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 66 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 38 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHANSON, PAUL (CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Maniilaq Association | Kotzebue, AK | $6.78M |
| Maniilaq Association | Kotzebue, AK | $5.79M |
| Maniilaq Association | Kotzebue, AK | $3.17M |
| Huntsville Community Hospital, INC. | Huntsville, TX | $1.90M |
| Huntsville Community Hospital, INC. | Huntsville, TX | $864.17 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.